PluviaEndo

PluviaEndo is a biotechnology company developing oral, gut-restricted small molecules for the treatment of metabolic disorders, including obesity and type 2 diabetes. The company's platform focuses on stimulating the natural release of satiety hormones such as GLP-1, PYY, and CCK directly from the enteroendocrine cells in the gastrointestinal tract. By restricting the drug's action to the gut, PluviaEndo aims to provide the efficacy of injectable incretin mimetics with improved safety and tolerability. Their lead candidate, PE-001, is currently in pre-clinical development and is designed to mimic the physiological response to food intake. This approach potentially avoids the systemic side effects commonly associated with systemic GLP-1 receptor agonists. PluviaEndo is a spin-out from the University of Michigan and is supported by regional venture funds.